DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Safety and Efficacy Dose of Artesunate Used in Combination With LAPDAP Treatment of Uncomplicated Falciparum Malaria

Information source: GlaxoSmithKline
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Malaria

Intervention: Chlorproguanil-dapsone-artesunate (CDA) (Drug)

Phase: Phase 2

Status: Completed

Sponsored by: GlaxoSmithKline

Official(s) and/or principal investigator(s):
GSK Clinical Trials, M.D, Study Director, Affiliation: GlaxoSmithKline


Drug resistance to a range of antimalarial treatments has become widespread in Africa, South East Asia and South America. Because the rapid spread of drug resistance threatens a public health disaster in these areas of the world and to comply with the WHO-Roll Back Malaria policy of using Artemisinin-based combination therapies (ACT), there is a need to develop new, safe, effective and affordable ACT. Chlorproguanil-dapsone-artesunate (CDA)is a new ACT that is being developed for the treatment of uncomplicated falciparum malaria in Africa.

Clinical Details

Official title: An Open, Randomised, Multi-Centre Dose Ranging Phase II Study to Evaluate LAPDAP in Combination With Three Different Doses of Artesunate

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Treatment differences between 1,2, or 4mg/kg artesunate with a fixed dose of Chlorproguanil-dapsone (LAPDAP), as measured by determination of PC90 (time to achieve reduction of parasitaemia by 90% of baseline)

Secondary outcome: The key secondary efficacy endpoint is parasite viability (the proportion of ring-form parasites developing to schizonts) determined from rich adult data and confirmed with more sparse child data


Minimum age: 18 Years. Maximum age: 60 Years. Gender(s): Both.


Inclusion Criteria:

- Presentation to a healthcare facility with probable uncomplicated clinical malaria

- Adults aged between 18 and 60 years , or children aged between 12 and 120 months

- Weight between 5 and 85kg

- Pure [on microscopic grounds] screening P. falciparum parasitaemia in children from

25,000 to 100,000ul-1, or in adults from 10,000 to 100,000ul-1. [The parasitaemia range for adults was originally set at 25,000 to 100,000µl-1 and changed to 10,000 to 100,000µl-1 in protocol amendment 3 dated 05 May 2004]

- Written or oral witnessed consent obtained from subject, parent or guardian

- Compliance with the requirements of the protocol which include a hospital stay of 4

days and 3 nights and regular blood samples by finger-prick (children) or via a cannula (adults)

- A negative pregnancy test for women of child-bearing age on enrolment

Exclusion Criteria:

- Features of severe/complicated falciparum malaria

- Known allergy to sulphonamides

- Evidence of any concomitant infection at the time of presentation (including P. ovale

and P. malaria)

- Any other underlying disease that would compromise the diagnosis and the evaluation

of the response to the study medication (including clinical symptoms of immunosuppression, tuberculosis and bacterial infection)

- Treatment in the 28-days prior to screening with sulfadoxine/pyrimethamine (FANSIDAR,

CELOXINE), sulfalene/pyrimethamine (METAKELFIN), mefloquine-sulfadoxinepyrimethamine (FANSIMET), chloroquine* (NIVAQUINE); treatment in the 21-days prior to screening with mefloquine, or 7-days prior to screening with amodiaquine, halofantrine, quinine

(full course), atovaquone - proguanil, artemisinins, co-artemether, tetracycline or

clindamycin, or treatment for 5 half-lives prior to screening with drugs that have a potential anti-malarial activity (e. g. co-trimoxazole in the previous 60 hours)

- Use of an investigational drug within 30 days or 5 half-lives (whichever is longer)

prior to screening

- Previous participation in this study

- A positive pregnancy test at enrolment, women of child-bearing age who do not take a

pregnancy test or female subjects who are breast-feeding an infant for the duration of the study

Locations and Contacts

GSK Clinical Trials Call Center, Banjul PO Box 273, Gambia

GSK Clinical Trials Call Center, Blantyre PO Box 95, Malawi

Additional Information

Starting date: June 2003
Last updated: August 21, 2007

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017